These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Use of cyclosporine 0.05% in various ocular surface disorders]. Maĭchuk DIu; Vasil'eva OA; Shokirova MM Vestn Oftalmol; 2014; 130(2):68-71. PubMed ID: 24864503 [TBL] [Abstract][Full Text] [Related]
3. [A new approach for better comprehension of diseases of the ocular surface]. Baudouin C J Fr Ophtalmol; 2007 Mar; 30(3):239-46. PubMed ID: 17417148 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of the effects of olopatadine ophthalmic solution, 0.2% on the ocular surface of patients with allergic conjunctivitis and dry eye. Mah FS; O'Brien T; Kim T; Torkildsen G Curr Med Res Opin; 2008 Feb; 24(2):441-7. PubMed ID: 18167176 [TBL] [Abstract][Full Text] [Related]
5. The Importance of Preventing and Managing Tear Dysfunction Syndrome in Allergic Conjunctivitis and How to Tackle This Problem. Montero-Iruzubieta J; Sanchez Hernandez MC; Dávila I; Leceta A J Investig Allergol Clin Immunol; 2023 Dec; 33(6):439-445. PubMed ID: 38095493 [TBL] [Abstract][Full Text] [Related]
6. Evaluating the novel application of cyclosporine 0.1% in ocular surface disease. Boboridis KG; Konstas AGP Expert Opin Pharmacother; 2018 Jun; 19(9):1027-1039. PubMed ID: 29847195 [TBL] [Abstract][Full Text] [Related]
7. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Sall K; Stevenson OD; Mundorf TK; Reis BL Ophthalmology; 2000 Apr; 107(4):631-9. PubMed ID: 10768324 [TBL] [Abstract][Full Text] [Related]
10. Increasing importance of dry eye syndrome and the ideal artificial tear: consensus views from a roundtable discussion. Asbell PA Curr Med Res Opin; 2006 Nov; 22(11):2149-57. PubMed ID: 17076975 [TBL] [Abstract][Full Text] [Related]
11. Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease. Wang Y; Ogawa Y; Dogru M; Kawai M; Tatematsu Y; Uchino M; Okada N; Igarashi A; Kujira A; Fujishima H; Okamoto S; Shimazaki J; Tsubota K Bone Marrow Transplant; 2008 Feb; 41(3):293-302. PubMed ID: 17982500 [TBL] [Abstract][Full Text] [Related]
12. Three percent diquafosol ophthalmic solution as an additional therapy to existing artificial tears with steroids for dry-eye patients with Sjögren's syndrome. Yokoi N; Sonomura Y; Kato H; Komuro A; Kinoshita S Eye (Lond); 2015 Sep; 29(9):1204-12. PubMed ID: 26160526 [TBL] [Abstract][Full Text] [Related]
13. Ocular allergy as a risk factor for dry eye in adults and children. Villani E; Rabbiolo G; Nucci P Curr Opin Allergy Clin Immunol; 2018 Oct; 18(5):398-403. PubMed ID: 30015640 [TBL] [Abstract][Full Text] [Related]
14. Long-term rebamipide and diquafosol in two cases of immune-mediated dry eye. Yamane M; Ogawa Y; Fukui M; Kamoi M; Saijo-Ban Y; Yaguchi S; Mukai S; Kawakita T; Simmura S; Tsubota K Optom Vis Sci; 2015 Apr; 92(4 Suppl 1):S25-32. PubMed ID: 25785527 [TBL] [Abstract][Full Text] [Related]
15. Recent Patents and Emerging Therapeutics on Ocular Inflammation and Allergy. Agrahari V; Aulgur Z; Thukral S; Dhall N; Conley R; Mitra AK Recent Pat Inflamm Allergy Drug Discov; 2017; 11(2):92-106. PubMed ID: 28901856 [TBL] [Abstract][Full Text] [Related]
16. Keratitis in Dry Eye Disease and Topical Ciclosporin A. Leonardi A; Flamion B; Baudouin C Ocul Immunol Inflamm; 2017 Aug; 25(4):577-586. PubMed ID: 28146363 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Topical 0.05% Cyclosporine Eye Drops in the Treatment of Dry Eye Syndrome: A Systematic Review and Meta-analysis. Wan KH; Chen LJ; Young AL Ocul Surf; 2015 Jul; 13(3):213-25. PubMed ID: 26045239 [TBL] [Abstract][Full Text] [Related]
18. An update on dry eye disease molecular treatment: advances in drug pipelines. Colligris B; Crooke A; Huete-Toral F; Pintor J Expert Opin Pharmacother; 2014 Jul; 15(10):1371-90. PubMed ID: 24773445 [TBL] [Abstract][Full Text] [Related]
19. A New Ophthalmic Pharmaceutical Formulation, Topical Sulglycotide, Enhances the Ocular Mucin Secretion in Desiccation Stress-Mediated Dry Eye Disease. Lee H; Jeon S; Kim CE; Park YJ; Yang J Invest Ophthalmol Vis Sci; 2019 Mar; 60(4):1076-1087. PubMed ID: 30901389 [TBL] [Abstract][Full Text] [Related]
20. Diquafosol ophthalmic solution for dry eye treatment. Nakamura M; Imanaka T; Sakamoto A Adv Ther; 2012 Jul; 29(7):579-89. PubMed ID: 22843206 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]